[
  {
    "ts": null,
    "headline": "Tracking Saudi Sovereign Wealth Fund's 13F Portfolio - Q2 2025 Update",
    "summary": "PIFâs US 13F portfolio value declined to $23.81B, with Uber, Electronic Arts, Lucid, Take-Two, and ARM comprising 77% of assets. See more insights here.",
    "url": "https://finnhub.io/api/news?id=22e6b64b4657d5735d1a63216963e8b9802f2f4188e3ef18569f68660cb7686c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757545741,
      "headline": "Tracking Saudi Sovereign Wealth Fund's 13F Portfolio - Q2 2025 Update",
      "id": 136692857,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153211726/image_2153211726.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "PIFâs US 13F portfolio value declined to $23.81B, with Uber, Electronic Arts, Lucid, Take-Two, and ARM comprising 77% of assets. See more insights here.",
      "url": "https://finnhub.io/api/news?id=22e6b64b4657d5735d1a63216963e8b9802f2f4188e3ef18569f68660cb7686c"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Looks Like Hyper Growth At A Reasonable Price",
    "summary": "Hims & Hers' scalable model, product launches, and global expansion plans support its ambitious 2030 revenue and EBITDA targets. Read why HIMS stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=b347d0eae1acd3dc3ff822492b523fc3853dc74768ae7b9d3ab4dbac64d78ffa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757544722,
      "headline": "Hims & Hers Looks Like Hyper Growth At A Reasonable Price",
      "id": 136692091,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148954799/image_2148954799.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hims & Hers' scalable model, product launches, and global expansion plans support its ambitious 2030 revenue and EBITDA targets. Read why HIMS stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=b347d0eae1acd3dc3ff822492b523fc3853dc74768ae7b9d3ab4dbac64d78ffa"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets",
    "summary": "The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management. ICER is also assessing how these treatments affect additional obesity-related outcomes. In a draft report, the ICER determined that the drugs are cost-effective because, when added on to lifestyle modificatio",
    "url": "https://finnhub.io/api/news?id=1c10768124faae1b3df70ae8b86fb35ce39e70be5f8a9947005263971e78a4c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757539867,
      "headline": "Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets",
      "id": 136688575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management. ICER is also assessing how these treatments affect additional obesity-related outcomes. In a draft report, the ICER determined that the drugs are cost-effective because, when added on to lifestyle modificatio",
      "url": "https://finnhub.io/api/news?id=1c10768124faae1b3df70ae8b86fb35ce39e70be5f8a9947005263971e78a4c1"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.",
    "summary": "A new Trump administration crackdown on prescription drug ads directed at consumers could substantially drag on pharmaceutical revenues—if it’s successful at reining in the billions of dollars that drug companies spend on ads each year in the U.S.  It remains unclear what impact these government measures will have on direct-to-consumer drug ads—on which drugmakers spend more than $10 billion a year in the U.S.  U.S. courts have held that the ads are shielded by First Amendment speech protections, but in a note to investors late Tuesday, Raymond James healthcare policy analyst Chris Meekins wrote that the administration looks to be trying to kill drug advertising with “disclosure and rule-making.”",
    "url": "https://finnhub.io/api/news?id=83781c4c6edbf9d5214a2a3bd1c314075e02f999ffa209003a3348c114a1f94d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757533740,
      "headline": "Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.",
      "id": 136688576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A new Trump administration crackdown on prescription drug ads directed at consumers could substantially drag on pharmaceutical revenues—if it’s successful at reining in the billions of dollars that drug companies spend on ads each year in the U.S.  It remains unclear what impact these government measures will have on direct-to-consumer drug ads—on which drugmakers spend more than $10 billion a year in the U.S.  U.S. courts have held that the ads are shielded by First Amendment speech protections, but in a note to investors late Tuesday, Raymond James healthcare policy analyst Chris Meekins wrote that the administration looks to be trying to kill drug advertising with “disclosure and rule-making.”",
      "url": "https://finnhub.io/api/news?id=83781c4c6edbf9d5214a2a3bd1c314075e02f999ffa209003a3348c114a1f94d"
    }
  },
  {
    "ts": null,
    "headline": "Rate of employers covering weight-loss drugs is flat, Cigna says",
    "summary": "(Reuters) -Cigna said on Wednesday the percentage of employers paying for obesity drugs has remained flat year-over-year, though the health insurer still sees an uptick in demand for the wildly popular treatments.  More than 50% of its Evernorth unit's clients, a group that includes large employers and health plans, cover the drugs for weight management, Chief Financial Officer Brian Evanko said at the Morgan Stanley Healthcare Conference.  Within Cigna Healthcare, its health benefits only segment, which caters more to smaller employers, only about 15% to 20% of clients offer coverage of the medications, he said.",
    "url": "https://finnhub.io/api/news?id=0f1164b9dd925462d2f21357cbdfbdf201295b2ad51dc15aae7816df07d0a6c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757532763,
      "headline": "Rate of employers covering weight-loss drugs is flat, Cigna says",
      "id": 136688577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Cigna said on Wednesday the percentage of employers paying for obesity drugs has remained flat year-over-year, though the health insurer still sees an uptick in demand for the wildly popular treatments.  More than 50% of its Evernorth unit's clients, a group that includes large employers and health plans, cover the drugs for weight management, Chief Financial Officer Brian Evanko said at the Morgan Stanley Healthcare Conference.  Within Cigna Healthcare, its health benefits only segment, which caters more to smaller employers, only about 15% to 20% of clients offer coverage of the medications, he said.",
      "url": "https://finnhub.io/api/news?id=0f1164b9dd925462d2f21357cbdfbdf201295b2ad51dc15aae7816df07d0a6c7"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up",
    "summary": "The pharmaceutical giant is slashing 11% of its workforce as it continues to lose market share.",
    "url": "https://finnhub.io/api/news?id=f403bfbe8f2bed9cbb2f6eae7398c521f35197ad9beecddb8c9adcc6027e41db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757532600,
      "headline": "Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up",
      "id": 136703788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical giant is slashing 11% of its workforce as it continues to lose market share.",
      "url": "https://finnhub.io/api/news?id=f403bfbe8f2bed9cbb2f6eae7398c521f35197ad9beecddb8c9adcc6027e41db"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Unveils Lilly TuneLab AI Platform With US$1 Billion Data Investment",
    "summary": "Eli Lilly (LLY) saw notable developments in September, with the launch of Lilly TuneLab, an AI/ML platform designed to enhance drug discovery, showcasing the company's commitment to technological innovation. The company's recent positive clinical trial results, including Jaypirca's Phase 3 success, and the FDA's Breakthrough Therapy designation for olomorasib, further reinforced its robust pipeline. Amid these events, LLY's share price rose 20% over the past month, echoing a strong market...",
    "url": "https://finnhub.io/api/news?id=29eb12803004b8d47c14e7188693ec0e3e64c482601c680d8deb09fa36f8c763",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757531521,
      "headline": "Eli Lilly (LLY) Unveils Lilly TuneLab AI Platform With US$1 Billion Data Investment",
      "id": 136688578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) saw notable developments in September, with the launch of Lilly TuneLab, an AI/ML platform designed to enhance drug discovery, showcasing the company's commitment to technological innovation. The company's recent positive clinical trial results, including Jaypirca's Phase 3 success, and the FDA's Breakthrough Therapy designation for olomorasib, further reinforced its robust pipeline. Amid these events, LLY's share price rose 20% over the past month, echoing a strong market...",
      "url": "https://finnhub.io/api/news?id=29eb12803004b8d47c14e7188693ec0e3e64c482601c680d8deb09fa36f8c763"
    }
  },
  {
    "ts": null,
    "headline": "Ascletis’ GLP-1RA shows promise with quarterly dosing schedule",
    "summary": "The Chinese biotech will now pursue the further development of ASC30 in obesity for use as a maintenance and treatment therapy.",
    "url": "https://finnhub.io/api/news?id=238a28f2e2a91007961d58fade4353094dd694bdd0a50a271f441333483ce3d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757524004,
      "headline": "Ascletis’ GLP-1RA shows promise with quarterly dosing schedule",
      "id": 136688579,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Chinese biotech will now pursue the further development of ASC30 in obesity for use as a maintenance and treatment therapy.",
      "url": "https://finnhub.io/api/news?id=238a28f2e2a91007961d58fade4353094dd694bdd0a50a271f441333483ce3d6"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds",
    "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.",
    "url": "https://finnhub.io/api/news?id=53beb53f11265427115a0250ab7c4556b4541be721f51f199478620ba03e385e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757520480,
      "headline": "5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds",
      "id": 136688580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.",
      "url": "https://finnhub.io/api/news?id=53beb53f11265427115a0250ab7c4556b4541be721f51f199478620ba03e385e"
    }
  },
  {
    "ts": null,
    "headline": "Is NVO's Major Restructuring Plan an Indication to Sell the Stock?",
    "summary": "Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.",
    "url": "https://finnhub.io/api/news?id=e1c674146ae1d199e0364ca42c8203a7c45ebe4cb452b9164bb9c206d19d8f83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757518080,
      "headline": "Is NVO's Major Restructuring Plan an Indication to Sell the Stock?",
      "id": 136688581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.",
      "url": "https://finnhub.io/api/news?id=e1c674146ae1d199e0364ca42c8203a7c45ebe4cb452b9164bb9c206d19d8f83"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic maker Novo Nordisk to cut 11% of workforce",
    "summary": "The Danish pharmaceutical titan will cut 9,000 jobs as rival weight-loss drugs flood the market",
    "url": "https://finnhub.io/api/news?id=2ea363b8ab46cb7a3d2c634f0900f7f33dcb7b71a8b41bf1cd3a9dbaf5615f10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757517024,
      "headline": "Ozempic maker Novo Nordisk to cut 11% of workforce",
      "id": 136688582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Danish pharmaceutical titan will cut 9,000 jobs as rival weight-loss drugs flood the market",
      "url": "https://finnhub.io/api/news?id=2ea363b8ab46cb7a3d2c634f0900f7f33dcb7b71a8b41bf1cd3a9dbaf5615f10"
    }
  },
  {
    "ts": null,
    "headline": "8MM Alzheimer's Disease Market Drug Forecast and Market Analysis 2025-2033 | Eisai, Biogen, and Lilly to Lead, Novel Late-stage Pipeline Drugs Will Be a Key Driver, Opportunities in Unmet Needs",
    "summary": "Alzheimer’s market growth opportunities lie in developing disease-modifying treatments and anti-Aβ monoclonal antibodies, driven by unmet needs in AD therapies. The US and China dominate sales, with future expansions anticipated, requiring strategic in-licensing, partnerships, and innovation to capture growing demand.Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The \"Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update\" report has been added to ResearchAndMarkets.com's offer",
    "url": "https://finnhub.io/api/news?id=aaad952cbb15e2f4f9d4507cc0b93b4e08e3c1f357fa18da6911de439d32c95e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757516580,
      "headline": "8MM Alzheimer's Disease Market Drug Forecast and Market Analysis 2025-2033 | Eisai, Biogen, and Lilly to Lead, Novel Late-stage Pipeline Drugs Will Be a Key Driver, Opportunities in Unmet Needs",
      "id": 136688583,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Alzheimer’s market growth opportunities lie in developing disease-modifying treatments and anti-Aβ monoclonal antibodies, driven by unmet needs in AD therapies. The US and China dominate sales, with future expansions anticipated, requiring strategic in-licensing, partnerships, and innovation to capture growing demand.Dublin, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The \"Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update\" report has been added to ResearchAndMarkets.com's offer",
      "url": "https://finnhub.io/api/news?id=aaad952cbb15e2f4f9d4507cc0b93b4e08e3c1f357fa18da6911de439d32c95e"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Restructuring And Reduced Guidance Set Up A Cleaner 2026",
    "summary": "Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=90b18f5ac4deeaaff9f3977b3ef1cf9c6fbea9f1e94925e899e890af41af5891",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757515764,
      "headline": "Novo Nordisk: Restructuring And Reduced Guidance Set Up A Cleaner 2026",
      "id": 136685831,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2213310229/image_2213310229.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S is poised for long-term growth despite job cuts and margin resets. Click here to find out why NVO stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=90b18f5ac4deeaaff9f3977b3ef1cf9c6fbea9f1e94925e899e890af41af5891"
    }
  },
  {
    "ts": null,
    "headline": "Oracle’s $230 Billion Market Cap Surge to Lift It Above JPMorgan",
    "summary": "If the stock’s 40% gain holds, Oracle would see its value rise by more than $230 billion to propel its market capitalization to roughly $916 billion, overtaking JPMorgan, Walmart Inc., Eli Lilly & Co. and Visa Inc.  While it would be the biggest intraday jump for Oracle since 1992, it would be its biggest single-session market value addition ever, according to data compiled by Bloomberg.",
    "url": "https://finnhub.io/api/news?id=e9474013c91952dffc30555f1f5f3f830ff08d75926ee7b4da46277b6b3bcb52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757515719,
      "headline": "Oracle’s $230 Billion Market Cap Surge to Lift It Above JPMorgan",
      "id": 136688567,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "If the stock’s 40% gain holds, Oracle would see its value rise by more than $230 billion to propel its market capitalization to roughly $916 billion, overtaking JPMorgan, Walmart Inc., Eli Lilly & Co. and Visa Inc.  While it would be the biggest intraday jump for Oracle since 1992, it would be its biggest single-session market value addition ever, according to data compiled by Bloomberg.",
      "url": "https://finnhub.io/api/news?id=e9474013c91952dffc30555f1f5f3f830ff08d75926ee7b4da46277b6b3bcb52"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Just Reclaimed the 50-Day Moving Average",
    "summary": "Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?",
    "url": "https://finnhub.io/api/news?id=28edc95d182fadfb23384da5aff6f15a74bed997160a927cf9dd8c038e7c548e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757514602,
      "headline": "Eli Lilly (LLY) Just Reclaimed the 50-Day Moving Average",
      "id": 136688585,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?",
      "url": "https://finnhub.io/api/news?id=28edc95d182fadfb23384da5aff6f15a74bed997160a927cf9dd8c038e7c548e"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy and Ozempic maker to cut 9,000 jobs amid stiff competition from Eli Lilly",
    "summary": "Novo Nordisk, the maker of weight loss drug Wegovy, will lay off about 9,000 people as it grapples with rising competition in the obesity market.",
    "url": "https://finnhub.io/api/news?id=a7586d381ad5dbe3e06d30e527b56d6ef81801269a6fd3bd1119adcbce586dbb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757513388,
      "headline": "Wegovy and Ozempic maker to cut 9,000 jobs amid stiff competition from Eli Lilly",
      "id": 136688586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk, the maker of weight loss drug Wegovy, will lay off about 9,000 people as it grapples with rising competition in the obesity market.",
      "url": "https://finnhub.io/api/news?id=a7586d381ad5dbe3e06d30e527b56d6ef81801269a6fd3bd1119adcbce586dbb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk slashes 11% of workforce as Eli Lilly pressure tightens",
    "summary": "The restructuring marks the first major action authorised by new CEO Mike Doustdar in a bid to turn the company’s fortunes around.",
    "url": "https://finnhub.io/api/news?id=a1109a6175150e910d5ce3320cfb78589d28a153172f9ba651a7a9ddc23772dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757508122,
      "headline": "Novo Nordisk slashes 11% of workforce as Eli Lilly pressure tightens",
      "id": 136688587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The restructuring marks the first major action authorised by new CEO Mike Doustdar in a bid to turn the company’s fortunes around.",
      "url": "https://finnhub.io/api/news?id=a1109a6175150e910d5ce3320cfb78589d28a153172f9ba651a7a9ddc23772dd"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Job Cuts, Profit Guidance Shock - Why Investors Should Hold Firm",
    "summary": "Discover why Novo Nordisk A/Sâs 2025 restructuring and staff cuts shouldn't deter investors. Click to explore the long-term NVO growth potential and outlook.",
    "url": "https://finnhub.io/api/news?id=c2eac514284ad95a72c7729649667ef81b0c884a2bcb6e87d90cf5eded8ad837",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757506466,
      "headline": "Novo Nordisk: Job Cuts, Profit Guidance Shock - Why Investors Should Hold Firm",
      "id": 136685040,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Novo Nordisk A/Sâs 2025 restructuring and staff cuts shouldn't deter investors. Click to explore the long-term NVO growth potential and outlook.",
      "url": "https://finnhub.io/api/news?id=c2eac514284ad95a72c7729649667ef81b0c884a2bcb6e87d90cf5eded8ad837"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 and Nasdaq notch record-high closes as Oracle soars on AI optimism",
    "summary": "The S&P 500 and Nasdaq notched record-high closes on Wednesday, as Oracle surged and cooler-than-expected inflation data supported expectations the U.S. Federal Reserve will cut interest rates next week.  Data center power suppliers also benefited, with Constellation Energy, Vistra and GE Vernova all rising more than 6%.  Traders fully expect the Fed to cut interest rates by at least 25 basis points at its policy meeting next week, with a 10% chance the central bank could cut by 50 basis points, CME's FedWatch tool showed.",
    "url": "https://finnhub.io/api/news?id=0301af54c0523f0d7451af992fdeb3dcec52a8cd5c427d74dc8e1b40a4fdb860",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757501259,
      "headline": "S&P 500 and Nasdaq notch record-high closes as Oracle soars on AI optimism",
      "id": 136688588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 and Nasdaq notched record-high closes on Wednesday, as Oracle surged and cooler-than-expected inflation data supported expectations the U.S. Federal Reserve will cut interest rates next week.  Data center power suppliers also benefited, with Constellation Energy, Vistra and GE Vernova all rising more than 6%.  Traders fully expect the Fed to cut interest rates by at least 25 basis points at its policy meeting next week, with a 10% chance the central bank could cut by 50 basis points, CME's FedWatch tool showed.",
      "url": "https://finnhub.io/api/news?id=0301af54c0523f0d7451af992fdeb3dcec52a8cd5c427d74dc8e1b40a4fdb860"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies",
    "summary": "The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.View on euronews",
    "url": "https://finnhub.io/api/news?id=72448cec29234f298045307921d74fdb0f3ce0d8f1802868f4cffa4b8346812e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757499823,
      "headline": "Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies",
      "id": 136688589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.View on euronews",
      "url": "https://finnhub.io/api/news?id=72448cec29234f298045307921d74fdb0f3ce0d8f1802868f4cffa4b8346812e"
    }
  },
  {
    "ts": null,
    "headline": "Wegovy-maker Novo Nordisk to slash 9,000 jobs as competition grows",
    "summary": "STORY: Novo Nordisk wants to slim down its workforce.The weight-loss drug giant said Wednesday it will cut 9,000 jobs - or 11.5% of its staff.It's part of a restructure to save about $1.3 billion yearly.Novo has reached a key moment in its development as its star drugs lose market share.Sales growth has also slowed, especially in the U.S. - home of key rival Eli Lilly.Novo said the overhaul will simplify the company and improve the speed of decision-making.It also argues it can reallocate resources towards growth opportunities.CEO Mike Doustdar took charge last month.He said in a statement the company must evolve as their target markets have changed, particularly in obesity.Novo shares fell heavily in July when the firm issued a profit warning.Operating profit growth this year is now expected at between 4% and 10%, down from between 10% and 16% seen last month.That is solely due to the restructuring costs.Novo shares have fallen nearly 46% since the start of the year.",
    "url": "https://finnhub.io/api/news?id=9ab06a8542da7abeea87b8953f39690ac2295919b12c11bb678d298310ed9ec3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757499505,
      "headline": "Wegovy-maker Novo Nordisk to slash 9,000 jobs as competition grows",
      "id": 136688590,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk wants to slim down its workforce.The weight-loss drug giant said Wednesday it will cut 9,000 jobs - or 11.5% of its staff.It's part of a restructure to save about $1.3 billion yearly.Novo has reached a key moment in its development as its star drugs lose market share.Sales growth has also slowed, especially in the U.S. - home of key rival Eli Lilly.Novo said the overhaul will simplify the company and improve the speed of decision-making.It also argues it can reallocate resources towards growth opportunities.CEO Mike Doustdar took charge last month.He said in a statement the company must evolve as their target markets have changed, particularly in obesity.Novo shares fell heavily in July when the firm issued a profit warning.Operating profit growth this year is now expected at between 4% and 10%, down from between 10% and 16% seen last month.That is solely due to the restructuring costs.Novo shares have fallen nearly 46% since the start of the year.",
      "url": "https://finnhub.io/api/news?id=9ab06a8542da7abeea87b8953f39690ac2295919b12c11bb678d298310ed9ec3"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic maker to cut 9,000 jobs",
    "summary": "The drugmaker behind Ozempic is to cut thousands of jobs as it grapples with a plummeting share price and competition to its breakthrough weight-loss injections.",
    "url": "https://finnhub.io/api/news?id=2832a3b981b2e80f4a4c96b3a057312a89598b82781c727143c9474c51f6464d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757496459,
      "headline": "Ozempic maker to cut 9,000 jobs",
      "id": 136688591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker behind Ozempic is to cut thousands of jobs as it grapples with a plummeting share price and competition to its breakthrough weight-loss injections.",
      "url": "https://finnhub.io/api/news?id=2832a3b981b2e80f4a4c96b3a057312a89598b82781c727143c9474c51f6464d"
    }
  },
  {
    "ts": null,
    "headline": "Our H2 2025 Top Ideas",
    "summary": "US economic slowdown heightens stagflation risks and limits market upside. Check out top investment picks to navigate headwinds.",
    "url": "https://finnhub.io/api/news?id=fb69cef8ea70c55f9fdf77e0d71b4836dddd51554c55237bf208023e0294c0ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757494815,
      "headline": "Our H2 2025 Top Ideas",
      "id": 136684383,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189067320/image_2189067320.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "US economic slowdown heightens stagflation risks and limits market upside. Check out top investment picks to navigate headwinds.",
      "url": "https://finnhub.io/api/news?id=fb69cef8ea70c55f9fdf77e0d71b4836dddd51554c55237bf208023e0294c0ca"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk slashes 9,000 jobs to slim down in fierce weight-loss drug battle",
    "summary": "Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to reignite growth and fend off intense competition from U.S. rival Eli Lilly and a wave of compounded copycat drugs.  The restructuring, including the largest layoff in Denmark's history, is expected to save 8 billion Danish crowns ($1.25 billion) annually and comes as Novo Nordisk is battling to revive its fortunes under a new CEO after it lost its lead to Eli Lilly in the obesity and diabetes markets.  Sales growth has stalled and shares have slumped, knocking $450 billion off the Danish company's market cap since the middle of last year and hurting the local economy.",
    "url": "https://finnhub.io/api/news?id=171779b93c28091131934687743cca5b61099ced554bc3c42565b5f4e668b77d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757484440,
      "headline": "Novo Nordisk slashes 9,000 jobs to slim down in fierce weight-loss drug battle",
      "id": 136688592,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk, the maker of blockbuster weight-loss drug Wegovy, said on Wednesday it will cut 9,000 jobs in a bid to reignite growth and fend off intense competition from U.S. rival Eli Lilly and a wave of compounded copycat drugs.  The restructuring, including the largest layoff in Denmark's history, is expected to save 8 billion Danish crowns ($1.25 billion) annually and comes as Novo Nordisk is battling to revive its fortunes under a new CEO after it lost its lead to Eli Lilly in the obesity and diabetes markets.  Sales growth has stalled and shares have slumped, knocking $450 billion off the Danish company's market cap since the middle of last year and hurting the local economy.",
      "url": "https://finnhub.io/api/news?id=171779b93c28091131934687743cca5b61099ced554bc3c42565b5f4e668b77d"
    }
  },
  {
    "ts": null,
    "headline": "UBS Sees $15 Billion Sales Potential for Eli Lilly’s (LLY) Obesity Treatment Orforglipron",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the most active stocks to buy according to Wall Street analysts. Following favorable Phase 3 trial findings for Eli Lilly & Company (NYSE:LLY)’s obesity treatment, UBS reaffirmed its Buy rating and $895 price target on the company on August 27. The pharmaceutical company revealed topline results from its […]",
    "url": "https://finnhub.io/api/news?id=dcc2b8f718eb7261abb0f44294cdcc00f692c9d6abdd8425787660482eb313a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757480160,
      "headline": "UBS Sees $15 Billion Sales Potential for Eli Lilly’s (LLY) Obesity Treatment Orforglipron",
      "id": 136688593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the most active stocks to buy according to Wall Street analysts. Following favorable Phase 3 trial findings for Eli Lilly & Company (NYSE:LLY)’s obesity treatment, UBS reaffirmed its Buy rating and $895 price target on the company on August 27. The pharmaceutical company revealed topline results from its […]",
      "url": "https://finnhub.io/api/news?id=dcc2b8f718eb7261abb0f44294cdcc00f692c9d6abdd8425787660482eb313a2"
    }
  }
]